Abstract
Renal cell carcinoma (RCC) represents 2 to 3% of cancers worldwide, and is among the top ten most diagnosed, with a higher incidence in Western Countries. Among these, clear cell renal carcinoma (CCRcc) is the predominant histology seen, corresponding to 85% of cases. Treatment is with targeted therapy against vascular endothelial growth factor (VEGF) and with new immunotherapeutic agents…